ARTV · Artiva Biotherapeutics, Inc.

The thesis

Artiva Biotherapeutics ended the case that earlier coverage rested on. On 27 October 2026 the company discontinued development of AlloNK, its natural killer (NK) cell therapy, and said the Phase 3 rheumatoid arthritis trial will not start. The shares now depend on what the board's strategic review does with the cash that remains, and the narrative is dead as a drug story: the company cut about 94% of its workforce and cancelled its data presentation on the same day.

Artiva gave three reasons in its 8-K and release. Durability of clinical response in longer follow-up did not meet the company's required threshold. Two patients died (Grade 5 events). Enrollment was likely to be delayed.

The last adjusted close was $4.27 on 27 October 2026, which is 68.1% below the 52-week high of $13.39. The three-month change is -59.1%. Wedbush downgraded the shares to Neutral with a $4 target, and Needham downgraded them to Hold, both on 27 October 2026. This note's rating drops to the coverage-only level because the original catalysts (the 20-patient update and the Phase 3 start) no longer exist and the remaining outcome has no scheduled date.

Bullish and bearish views on Artiva Biotherapeutics, Inc.

The bull case on Artiva Biotherapeutics, Inc. (ARTV), in brief: Cash remains large. The bear case: The lead asset is stopped.

Bull case

• Cash remains large. Artiva reported about $319.1 million in cash, cash equivalents and investments at 30 September 2026 (preliminary, unaudited), per its 27 October 2026 8-K. A liquidation or cash-rich merger would be valued against that figure, less wind-down costs.
• A formal process is underway. The board is reviewing a merger, business combination, sale or licensing of assets, or dissolution and liquidation, with Leerink Partners advising (8-K, 27 October 2026). Any announced transaction would give the shares a priced outcome.
• Spending falls sharply. The 94% headcount cut announced 27 October 2026 is aimed at preserving capital, which slows the decline in cash.
• Data may still have value. Artiva said updated data may be presented at future meetings depending on the strategic process (release, 27 October 2026), so asset or licensing interest is not ruled out.

Bear case

• The lead asset is stopped. AlloNK development is discontinued, the Phase 3 trial of about 150 refractory rheumatoid arthritis patients will not start, and no further patients will be dosed in any ongoing AlloNK study (release, 27 October 2026).
• Safety events were fatal. One Phase 2a basket-trial patient died of leukoencephalopathy after cyclophosphamide and fludarabine lymphodepletion, judged likely related to fludarabine-associated neurotoxicity by the investigator and an independent safety review. A second patient died suddenly about two months after starting treatment; the cause is undetermined (release, 27 October 2026).
• Response durability fell short. The company said longer-term follow-up did not meet its required threshold for continued development. That weakens the earlier 5-of-7 ACR50 result (a 50% improvement on American College of Rheumatology criteria) reported on 6 August 2026.
• Wind-down costs are unquantified. Artiva said it cannot reasonably estimate total charges for trial close-out, leases, other liabilities and staff reductions (8-K, 27 October 2026).
• Liquidation is a listed outcome. Dissolution and liquidation sits alongside merger and asset-sale options, and the company gave no assurance of any transaction.
• Analysts have moved down. Wedbush cut to Neutral with a $4 target and Needham cut to Hold on 27 October 2026, after Cantor Fitzgerald's Overweight and $40 target of 2 October 2026.

Price setup

The adjusted close was $4.27 on 27 October 2026. That is 68.1% below the 52-week high of $13.39, and the 14-day relative strength index (RSI, a 0–100 gauge of recent buying against selling) is 21.3, a reading that marks heavy selling. Nasdaq halted trading at 7:25 a.m. ET on 27 October 2026 pending news and resumed quotation after 7:45 a.m. ET.

The $5.50 weekly-close invalidation level in the 15 October 2026 note is superseded, because the business facts behind that note have changed. Wedbush's $4 target is the nearest published analyst valuation below the close. The shares sit close to it, so a daily close below $4.00 would put them under that valuation.

Company-reported cash is the main anchor for valuation, but the final figure depends on wind-down charges that the company has not estimated. Share-count and per-share cash figures are not in the company's 27 October 2026 release, so none is given here.

Crowding evidence is limited. Artiva raised about $300 million in an underwritten offering in May 2026 (Q2 2026 results, 6 August 2026), and the shares have fallen since. No SEC Form 4 insider filings were available for this review.

Catalysts, next 30 days

• ~16 November 2026 (est.): Form 10-Q for the quarter ended 30 September 2026. It carries final cash, wind-down charges and lease and severance obligations. The date is an estimate from filing deadlines.
• 9 November 2026: investor webcast, cancelled. Artiva cancelled it on 27 October 2026, and the ACR Convergence 2026 data presentation was cancelled too.
• Undated: strategic review outcome. The company will update only when the board approves a course of action, the process ends or disclosure is required by law. The earlier year-end 2026 milestones for the 20-patient update and Phase 3 start no longer apply.

What would change the view

The low rating rests on the view that the shares are more likely to lag the S&P 500 over the next three months, because the remaining value depends on an undated review and unquantified wind-down costs. That view would be wrong if Artiva announces a cash-based transaction or a liquidation payout above the $4.27 close of 27 October 2026, or if the 10-Q shows wind-down charges small enough to leave most of the $319.1 million for stockholders.

A daily close below $4.00, the level of Wedbush's new target, would show the market pricing the shares under the latest analyst valuation. Fresh safety disclosures or litigation tied to the two deaths would add to the downside case.

What it trades with

Artiva trades on company-specific news, not on sector direction. The next moves depend on the Form 10-Q and the strategic review rather than on cell-therapy or autoimmune peers. Other clinical-stage biotechs that stopped their lead programs and opened strategic reviews are the closest comparison, but no peer data is cited here, so no relationship is claimed.